SCYNEXIS (SCYX) News Today $1.03 -0.01 (-0.96%) Closing price 04:00 PM EasternExtended Trading$1.03 0.00 (0.00%) As of 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period SCYNEXIS (SCYX) to Release Earnings on ThursdayMarch 25 at 2:03 AM | americanbankingnews.comStockNews.com Downgrades SCYNEXIS (NASDAQ:SCYX) to SellMarch 24 at 1:55 AM | americanbankingnews.comResearch Analysts Offer Predictions for SCYNEXIS FY2029 EarningsMarch 18, 2025 | americanbankingnews.comSCYNEXIS Full Year 2024 Earnings: Misses ExpectationsMarch 14, 2025 | finance.yahoo.comSCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 12, 2025 | markets.businessinsider.comSCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 12, 2025 | globenewswire.comSCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal InfectionsDecember 18, 2024 | markets.businessinsider.comMaxim Group Keeps Their Buy Rating on SCYNEXIS (SCYX)December 5, 2024 | markets.businessinsider.comSCYNEXIS’s Strong Financial Position and Strategic Advancements Drive Buy RatingNovember 9, 2024 | markets.businessinsider.comSCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 6, 2024 | globenewswire.comInvestors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five yearsOctober 30, 2024 | finance.yahoo.comSCYNEXIS (NASDAQ:SCYX) Shares Pass Above Fifty Day Moving Average - Should You Sell?SCYNEXIS (NASDAQ:SCYX) Stock Passes Above 50-Day Moving Average - Here's WhyOctober 22, 2024 | marketbeat.comSCYNEXIS (NASDAQ:SCYX) Share Price Passes Below 200-Day Moving Average - Here's WhySCYNEXIS (NASDAQ:SCYX) Stock Passes Below 200 Day Moving Average - What's Next?October 12, 2024 | marketbeat.comSCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual SummitOctober 10, 2024 | globenewswire.comFederated Hermes, Inc. Expands Stake in SCYNEXIS IncOctober 7, 2024 | finance.yahoo.comSCYNEXIS (NASDAQ:SCYX) Shares Pass Below Two Hundred Day Moving Average - Here's What HappenedSCYNEXIS (NASDAQ:SCYX) Stock Price Passes Below 200-Day Moving Average - Here's WhyOctober 4, 2024 | marketbeat.comSCYNEXIS (NASDAQ:SCYX) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comSCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024October 3, 2024 | globenewswire.comSCYNEXIS (NASDAQ:SCYX) Shares Pass Below 200 Day Moving Average of $1.82SCYNEXIS (NASDAQ:SCYX) Stock Price Crosses Below 200-Day Moving Average of $1.82September 25, 2024 | marketbeat.comSCYNEXIS, Inc. (NASDAQ:SCYX) CEO Gonzalez David Angulo Acquires 20,000 SharesSeptember 17, 2024 | insidertrades.comSCYNEXIS (NASDAQ:SCYX) Shares Cross Below 200 Day Moving Average of $1.83SCYNEXIS (NASDAQ:SCYX) Stock Crosses Below Two Hundred Day Moving Average of $1.83September 13, 2024 | marketbeat.comSCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment ConferenceAugust 27, 2024 | globenewswire.comBuy Rating Affirmed for SCYNEXIS Amid Antifungal Progress and Market PotentialAugust 13, 2024 | markets.businessinsider.comSCYNEXIS (NASDAQ:SCYX) Downgraded to "Sell" at StockNews.comStockNews.com cut SCYNEXIS from a "hold" rating to a "sell" rating in a research report on Monday.August 12, 2024 | marketbeat.comSCYNEXIS, Inc. (SCYX) stock historical prices & data – Yahoo FinanceAugust 9, 2024 | au.finance.yahoo.comSCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 9, 2024 | markets.businessinsider.comSCYX Stock Earnings: SCYNEXIS Misses EPS, Misses Revenue for Q2 2024August 9, 2024 | investorplace.comSCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 8, 2024 | globenewswire.comScynexis IncJuly 25, 2024 | money.usnews.comSCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study ReportsJuly 23, 2024 | globenewswire.com3 Stocks Under $10 With the Potential for Massive GainsJuly 22, 2024 | investorplace.com3 Stocks Under $10 With the Potential for Massive GainsJuly 22, 2024 | investorplace.com3 Dirt-Cheap Drug Developers With Blockbuster PotentialJuly 11, 2024 | investorplace.com7 Undervalued Biotech Stocks to Buy for Big-Time ReturnsJuly 1, 2024 | investorplace.comSCYNEXIS (NASDAQ:SCYX) Stock Price Passes Below Fifty Day Moving Average of $2.01SCYNEXIS (NASDAQ:SCYX) Share Price Passes Below 50 Day Moving Average of $2.01June 25, 2024 | marketbeat.comHidden Gems: 3 Under-$10 Stocks Poised for 500% Growth by 2025May 31, 2024 | investorplace.comDecheng Capital LLC Purchases New Holdings in SCYNEXIS, Inc. (NASDAQ:SCYX)Decheng Capital LLC purchased a new stake in shares of SCYNEXIS, Inc. (NASDAQ:SCYX - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 555,555 shares of the company's stock, valued at approximately $1,239,000. SCYNEXIS comprMay 30, 2024 | marketbeat.com3 Stocks Under $10 With Mammoth Growth ProspectsMay 23, 2024 | investorplace.comBuy Recommendation: Scynexis’s Ibrexafungerp Promises Market Breakthrough and Financial GrowthMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Scynexis on Robust Financials and Promising Antifungal PipelineMay 10, 2024 | markets.businessinsider.comSCYNEXIS, Inc. Forecasted to Earn FY2025 Earnings of $0.07 Per Share (NASDAQ:SCYX)SCYNEXIS, Inc. (NASDAQ:SCYX - Free Report) - Stock analysts at Brookline Capital Management lifted their FY2025 earnings estimates for SCYNEXIS in a research report issued on Wednesday, May 8th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will post earnings perMay 10, 2024 | marketbeat.comSCYX Stock Earnings: SCYNEXIS Beats EPS, Misses Revenue for Q1 2024May 9, 2024 | investorplace.comSCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 8, 2024 | markets.businessinsider.comInvestors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 87% over the last five yearsMay 8, 2024 | finance.yahoo.comSCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)April 30, 2024 | finance.yahoo.comSCYNEXIS, Inc. (SCYX)April 20, 2024 | finance.yahoo.comBuy Rating Affirmed for SCYNEXIS on Strong Financials and Promising Pipeline ProspectsApril 12, 2024 | markets.businessinsider.comSCYNEXIS, Inc. (NASDAQ:SCYX) Stake Trimmed by Stonepine Capital Management LLCStonepine Capital Management LLC lowered its position in SCYNEXIS, Inc. (NASDAQ:SCYX - Free Report) by 52.5% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,355,186 shares of the company's stock after selling 1,497,413 shares during tApril 9, 2024 | marketbeat.comSCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)April 9, 2024 | globenewswire.comFY2024 EPS Estimates for SCYNEXIS, Inc. Cut by Analyst (NASDAQ:SCYX)SCYNEXIS, Inc. (NASDAQ:SCYX - Free Report) - Equities researchers at Cantor Fitzgerald dropped their FY2024 EPS estimates for shares of SCYNEXIS in a note issued to investors on Monday, April 1st. Cantor Fitzgerald analyst L. Chen now forecasts that the company will earn ($0.46) per share for theApril 4, 2024 | marketbeat.com Remove Ads Get SCYNEXIS News Delivered to You Automatically Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter. Email Address SCYX Media Mentions By Week SCYX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SCYX News Sentiment▼0.500.68▲Average Medical News Sentiment SCYX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SCYX Articles This Week▼41▲SCYX Articles Average Week Remove Ads Get SCYNEXIS News Delivered to You Automatically Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ADCT News MOLN News CYBN News CCCC News SCPH News IVA News HURA News GLSI News LRMR News CGEN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SCYX) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SCYNEXIS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SCYNEXIS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
